Skip to main content

Table 4 The difference in headache practice based on experiences using CGRPmAbs

From: CGRP-monoclonal antibodies in Japan: insights from an online survey of physician members of the Japanese headache society

Item

Experienced (n = 320)

Not experienced (n = 77)

p-value

Length of the patients' first appointments, min

23.6 ± 9.7

23.1 ± 8.5

0.6758

Length of the patients' follow-up appointments, min

8.8 ± 3.6

10.0 ± 4.7

0.012

No. of patients with migraine who are followed up regularlya

50 [20, 150]

10 [5, 20]

<0.0001

Age, yrs

20 s

2, 0.6%

1, 1.3%

0.0006

30 s

19, 5.9%

13, 16.9%

40 s

87, 27.2%

31, 40.3%

50 s

113, 35.3%

18, 23.4%

 ≥ 60 s

99, 30.9%

14, 18.2%

Years of headache practice

 < 5 yrs

14, 4.4%

10, 13.0%

0.0004

 ≥ 5 and < 10 yrs

24, 7.5%

14, 18.2%

 ≥ 10 and < 20 yrs

101, 31.6%

24, 31.2%

 ≥ 20 yrs

181, 56.6%

29, 37.7%

Years of JHS membership

 < 1 yrs

30, 9.4%

22, 28.6%

 < 0.0001

 ≥ 1 and < 5 yrs

49, 15.3%

21, 27.3%

 ≥ 5 and < 10 yrs

58, 18.1%

15, 19.5%

 ≥ 10 yrs

183, 57.2%

19, 24.7%

Boards

 ≥ 1

311, 97.2%

63, 81.8%

<0.0001

  1. aEight and one answers were excluded from the 'Experienced' and 'Not experienced' groups, respectively. The data are presented as mean ± standard deviation or median [first quartile, third quartile]
  2. No Number, JHS Japan Headache Society, min minute, yrs years, CGRPmAb Anti-calcitonin gene-related peptide monoclonal antibody